Explore

Trendline Trendline
Partner Therapeutics Gains FDA Approval for Bizengri in Treating Advanced Cholangiocarcinoma

Partner Therapeutics Gains FDA Approval for Bizengri in Treating Advanced Cholangiocarcinoma

Partner Therapeutics Gains FDA Approval for Bizengri in Treating Advanced Cholangiocarcinoma
Trendline Trendline
Partner Therapeutics' Bizengri Approved for Rare Bile Duct Cancer

Partner Therapeutics' Bizengri Approved for Rare Bile Duct Cancer

Partner Therapeutics' Bizengri Approved for Rare Bile Duct Cancer
Trendline Trendline
FDA Approves Partner Therapeutics' Bizengri for Ultra-Rare Cancer Following Priority Voucher

FDA Approves Partner Therapeutics' Bizengri for Ultra-Rare Cancer Following Priority Voucher

FDA Approves Partner Therapeutics' Bizengri for Ultra-Rare Cancer Following Priority Voucher
Trendline Trendline
Zai Lab Secures FDA Fast Track for Zocilurtatug Pelitecan in Treating Aggressive Cancers

Zai Lab Secures FDA Fast Track for Zocilurtatug Pelitecan in Treating Aggressive Cancers

Zai Lab Secures FDA Fast Track for Zocilurtatug Pelitecan in Treating Aggressive Cancers
Trendline Trendline
Incyte to Present Key Hematology and Oncology Data at EHA 2026 Congress

Incyte to Present Key Hematology and Oncology Data at EHA 2026 Congress

Incyte to Present Key Hematology and Oncology Data at EHA 2026 Congress
Trendline Trendline
Verastem Oncology to Present at Key Investor Conferences in May 2026

Verastem Oncology to Present at Key Investor Conferences in May 2026

Verastem Oncology to Present at Key Investor Conferences in May 2026
Trendline Trendline
IMMEDIATE Therapeutics Strengthens Team to Advance Ischemic Therapy IMT-358

IMMEDIATE Therapeutics Strengthens Team to Advance Ischemic Therapy IMT-358

IMMEDIATE Therapeutics Strengthens Team to Advance Ischemic Therapy IMT-358
Trendline Trendline
Agenus Inc Reports Significant Revenue Growth and Profit in Q1 2026

Agenus Inc Reports Significant Revenue Growth and Profit in Q1 2026

Agenus Inc Reports Significant Revenue Growth and Profit in Q1 2026
Trendline Trendline
Agenus Advances BOT+BAL Immunotherapy with Phase 3 Trial and Strategic Collaboration

Agenus Advances BOT+BAL Immunotherapy with Phase 3 Trial and Strategic Collaboration

Agenus Advances BOT+BAL Immunotherapy with Phase 3 Trial and Strategic Collaboration
Trendline Trendline
Anixa Biosciences Reports Positive Survival Data from Phase 1 Trial of Lira-cel Ovarian Cancer Therapy

Anixa Biosciences Reports Positive Survival Data from Phase 1 Trial of Lira-cel Ovarian Cancer Therapy

Anixa Biosciences Reports Positive Survival Data from Phase 1 Trial of Lira-cel Ovarian Cancer Therapy
Trendline Trendline
IMMEDIATE Therapeutics Expands Leadership to Advance IMT-358 for Ischemic Therapy

IMMEDIATE Therapeutics Expands Leadership to Advance IMT-358 for Ischemic Therapy

IMMEDIATE Therapeutics Expands Leadership to Advance IMT-358 for Ischemic Therapy
Trendline Trendline
Coya Therapeutics Receives FDA Fast Track Designation for ALS Treatment COYA 302

Coya Therapeutics Receives FDA Fast Track Designation for ALS Treatment COYA 302

Coya Therapeutics Receives FDA Fast Track Designation for ALS Treatment COYA 302